A5039194712- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Radiopharmaceutical Chemistry and Applications
- HER2/EGFR in Cancer Research
- Head and Neck Cancer Studies
- Brain Metastases and Treatment
- Chronic Lymphocytic Leukemia Research
- Advanced Radiotherapy Techniques
- Multiple and Secondary Primary Cancers
- Gastric Cancer Management and Outcomes
- Lymphoma Diagnosis and Treatment
Ministry of Health
2020-2022
Russian Cancer Research Center NN Blokhin
2016-2019
Ministry of Health of the Russian Federation
2019
Now the number of patients receiving immunotherapy with checkpoint inhibitors is growing. At same time, clinicians increasingly encounter such a clinical phenomenon as pseudoprogression. Nowadays we have no radiological evidences The every case requires an individual decision.
The standard approach for stage IB and IIIIIA non-small cell lung cancer (NSCLC), associated with the high risk of relapse, after total resection is adjuvant chemotherapy, nowadays. 5-year survival benefit this about 5%, relapse reduces from 11 to 15%, depending on stage. However, rate within 5 years surgery chemotherapy in IBIIIA NSCLC up 70%. This fact requires search new solutions. efficacy safety profile targeted drugs metastatic show possibility use them as therapy early stages disease....
The urgency of the problem treating patients with lung cancer is caused by a steady increase in incidence and mortality rates population. Most NSCLC initially present locally advanced or disseminated disease. Currently, simultaneous chemoradiation therapy (CRT) standard for treatment NSCLC, which appears superior to single chemotherapy radiation therapy, while overall survival (OS) rate remains not high enough. Therefore, search optimal combinations chemotherapeutic drugs (CRT), as well...
Immunotherapy is the most promising method in treatment of lung cancer, especially connection with rapidly growing development monoclonal antibodies aimed at inhibiting immune checkpoints: anti-CTLA-4, anti-PD-1, anti-PD-L1. Classic immuno-mediated adverse events that occur this can affect several organs, including lungs. Pneumonitis a potentially life-threatening complication and often requires rapid high doses corticosteroids antibacterial drugs. We present case 67-year-old patient primary...
Molecularly targeted therapy with tyrosine kinase inhibitors (TKI) has been recognized as the optimal treatment option for patients EGFR-positive non-small-cell lung cancer (NSCLC). At present, 5 drugs of this group are available: first generation – erlotinib and gefitinib, second afatinib dacomitinib (not registered in Russia), third osimertinib. The have some peculiarities, refers to their antitumor activity, safety profile, resistance mechanisms. Knowledge these differences is necessary...
Introduction . The addition of durvalumab after chemoradiation therapy in unresectable stage III non-small-cell lung cancer (NSLC) is a new standard care. Aim Study the features and outcomes maintenance treatment chemoradiotherapy patients with NSCLC real-world clinical practice Russia. Materials methods 50 concurrent or sequential (CRT) were enrolled this observational retrospective study. Median follow up time at primary analysis was 12.4 months. Results A mean age study 61.2 years...
For more than 10 years, there have been no significant improvements in treatment outcomes for patients with inoperable locally advanced non-small cell lung cancer. At the moment, standard of this category is concurrent chemoradiation therapy. same time, 5-year overall survival rate varies range 15–25%. This indicator contributes to modernization existing approaches, as well search new ways stage III One promising areas combination therapy immunotherapy. Thus, use Imfinzi (durvalumab,...
The EGFR gene mutation occurs in 15% of patients with NSCLC. Tumors such a molecular genetic profile are characterized by high sensitivity to therapy tyrosine kinase inhibitors. However, the majority EGFRm+ develop resistance 1-2 generation TKI after 9-13 months. In our study, we considered an integrated regimen combined use chemotherapy and targeted as possible way overcome acquired tumor TKIs 1–2 generations. study included IIIB / IV stages NSCLC activating mutations. Initially there were...
Rebiopsies are not performed in currently clinical practice for the patients with advanced non-small cell lung cancer (NSCLC). However, identification of as an activating mutation, other molecular and genetic disorders can considerably change management prognosis these patients. Twenty-nine NSCLC after systemic therapy were rebiopsied samples studied a limited range alterations (sensitizing EGFR mutations, T790M, KRAS gene translocation ALK, ROS1, expression PD-L1). Results used making...
Major advances in the treatment of non-small-cell lung cancer (NSCLC) patients are associated with targeted therapy. It is both highly effective presence activating mutations tumor and generally well-tolerated. Serious adverse events recorded much less than chemotherapy. There significant differences toxicity profile. Both early detection proper timely correction complications therapies necessary for successful long-term metastatic NSCLC patients.
Relevance: Chemo-radiotherapy of patients with locally advanced forms NSCLC is the standard treatment and, all modern approaches to planning and implementing radiotherapy applied, a median survival more than 28 months can be achieved. Ways increase effectiveness are now associated local escalation radiation dose tumor implementation personalized approach concept in chemo-radiotherapy. Materials methods: Since 2013 chemo-radiotherapy has been performed for 51 lung cancer inoperable III stage:...
In the open prospective non-randomized single-center study we recruited patients with advanced NSCLC harboring EGFR mutations. Initially there were two months of treatment by gefitinib 250 mg daily. Then, after a 2-week drug-free period, 3 cycles paclitaxel 175 / m2 and carboplatin AUC5 administrated at days 71-113. Thereafter, was re-started on day 135 continued until disease progression. The primary endpoint progressive free survival (PFS) time. One-year PFS in all group included time...
Nowadays neoadjuvant immunotherapy is one of the main research areas in oncology. This interest supported by success check-point inhibitors treatment advanced and metastatic lung cancer. The postulate that achieves tumor devitalization before surgery confirmed a morphological assessment surgical material with gradation antitumor effect. In addition to affecting directly tumor, it also affects at potential micrometastases. A effect (MPR – major pathomorphological response, CPR complete...
Relevance: Chemo-radiotherapy of patients with locally advanced forms NSCLC is the standard treatment and, all modern approaches to planning and implementing radiotherapy applied, a median survival more than 28 months can be achieved. Ways increase effectiveness are now associated local escalation radiation dose tumor implementation personalized approach concept in chemo-radiotherapy. Material methods : Since 2013 chemo-radiotherapy has been performed for 51 lung cancer inoperable III stage:...
Lung cancer is a leader in the world terms of morbidity and mortality. Moreover, number patients with locally advanced forms non-small cell lung exceeds 30% all newly diagnosed cases. The standard treatment for inoperable stage III chemoradiotherapy. Currently, ways to increase effectiveness chemoradiotherapy are being considered, particular, local escalation radiation dose tumor, which allows personalizing approaches this category patients. One most common complications post-radiation...
The abscopal effect was described more than 50 years ago and is a phenomenon in which radiation therapy promotes the regression of metastatic foci remote from site radiation. For decades, this has been as rare, unexplained patients receiving therapy. Today, still an exceptional phenomenon: mechanism underlying it not fully understood. It believed that most likely associated with systemic immune responses occur under influence We present case 63-year-old patient advanced peripheral cancer...
Non-small cell lung cancer is a very heterogeneous group of diseases. When choosing an effective patient management strategy, oncologist focuses on the stage disease, morphological form tumor, as well its molecular genetic markers. Most targeted mutations in today are adenocarcinoma. The standard for detecting this type 2022 determination EGFR genes (18-21 exons) and BRAF (V600E), translocations ALK ROS1 genes, PD-L1 status regardless gender, age, history smoking. Often, detected advanced...